Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs BI 1181181 (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 12 Nov 2014 Results published in Vitae Pharmaceuticals media release.
    • 23 Oct 2014 Primary endpoint has been met (% change from baseline of beta amyloid protein 1-40 in cerebrospinal fluid at 24 hrs post dose), according to a Vitae Pharmaceuticals media release.
    • 23 Oct 2014 Top-line results published in a Vitae Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top